Open an account

Larimar Therapeutics

LRMR · NASDAQ

$2.44+$0.32 (+15.09%)TodayMarket closed ·
Prev close $2.12

About LRMR

Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing treatments for patients suffering from complex rare diseases using a novel cell penetrating peptide technology platform. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The firm intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Employees
71
Headquarters
Bala Cynwyd, Pennsylvania
Listed
Jun 19, 2014
Sector
Health Care
Industry
Biotechnology
Website
larimartx.com

LRMR key statistics

Market cap
253.47M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.71M
Volume
1.81M
Open price
$2.12
High today
$2.49
Low today
$2.10
52 Week high
$6.42
52 Week low
$1.92

Larimar Therapeutics (LRMR) at a glance

Larimar Therapeutics (LRMR) last traded at $2.44, with a market cap of 253.47M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.10 and $2.49. The current price is 16.2% above the day's low and 2.0% below its high.

Volume so far is 1.81M shares, in line with the average of 1.71M shares a day.

Over the past year Larimar Therapeutics has ranged from $1.92 to $6.42, and now sits 12% of the way up that range.

Larimar Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.30 per share against an estimate of -$0.3888.

The average analyst price target is $14.92, 511.4% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 11 analystsAvg $14.92
Low
$5.05
Now
$2.44
High
$27.30

LRMR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 29.9% on average.

  1. Q3 FY24: reported -$0.24 per share against an estimate of -$0.3825
  2. Q4 FY24: reported -$0.45 per share against an estimate of -$0.3234
  3. Q1 FY25: reported -$0.46 per share against an estimate of -$0.4266
  4. Q2 FY25: reported -$0.41 per share against an estimate of -$0.4898
  5. Q3 FY25: reported -$0.61 per share against an estimate of -$0.4121
  6. Q4 FY25: reported -$0.73 per share against an estimate of -$0.5171
  7. Q1 FY26: reported -$0.31 per share against an estimate of -$0.5457
  8. Q2 FY26: reported -$0.30 per share against an estimate of -$0.3888

LRMR news

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

  • Vandana Singh

    Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Avi Kapoor

    Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views

Similar companies

Companies in the same industry as Larimar Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.